Abstract. The prolactin-(Prl) lowering effect of nomifensine (Nom), an antidepressant drug which activates dopamine (DA) neurotransmission mainly by inhibiting DA re-uptake in the central nervous system (CNS), was investigated in normoprolactinaemic subjects, in subjects with physiological puerperal hyperprolactinaemia or pathological hyperprolactinaemia. Nom (200 mg po) administered to 23 normoprolactinaemic women induced a significant decrease in baseline Prl, which was more marked (about 50% inhibition at 120 min) and prompt (30 min) in the subjects who had 'high' Prl levels (>12<20 ng/ml) (13 subjects) than in those with 'low' Prl levels (\m=l e\12 ng/ml). Also in 9 puerperal women (postpartum day 2) oral administration of 200 mg 
Abstract. The prolactin-(Prl) lowering effect of nomifensine (Nom), an antidepressant drug which activates dopamine (DA) neurotransmission mainly by inhibiting DA re-uptake in the central nervous system (CNS), was investigated in normoprolactinaemic subjects, in subjects with physiological puerperal hyperprolactinaemia or pathological hyperprolactinaemia. Nom (200 mg po) administered to 23 normoprolactinaemic women induced a significant decrease in baseline Prl, which was more marked (about 50% inhibition at 120 min) and prompt (30 min) in the subjects who had 'high' Prl levels (>12<20 ng/ml) (13 subjects) than in those with 'low' Prl levels (\m=l e\12 ng/ml). Also in 9 puerperal women (postpartum day 2) oral administration of 200 mg Nom was followed by a clear-cut decrease of base-line Prl, which started at 30 min and reached nadir values at 150\p=n-\180 min (about 60% inhibition). Administration of Nom (200 mg po) to 47 subjects with pathological hyperprolactinaemia evidenced the presence of Nom non-responder (36 cases) or responder (11 cases) subjects. In 22 of the Nom non-responder subjects the existence of a Prl-se creting pituitary tumour was established at surgery by selective removal of an adenoma via the transsphenoidal route; of the 14 subjects who did not undergo surgery, 1 had evident and 5 had minor alterations of the sella turcica and, in addition, in 3 subjects the duration of amenorrhoea was longer than 5 years. Only 5 subjects of this group had no radiological alterations of the sella turcica, in presence of basal Prl levels ranging between 50\p=n-\126 ng/ml. In contrast, 10 out of the 11 Nom\x=req-\ responder subjects had a radiologically normal sella turcica and basal Prl levels lower than 50 ng/ml. Administration of 2-Br-\g=a\-ergocriptine(2.5 mg po), a direct stimulant of pituitary DA receptors, to subjects with pathological hyperprolactinaemia ( (Meites 1977; MacLeod & Login 1977) has led to the introduction of dopaminergic compounds as means capable of differentiating between 'functional' hyperprolactinaemia and prolactinomas (Faglia et al. 1977; Kleimberg et al. 1977; Frantz 1978) . However, drugs used so far 
(2) (6)
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(1) (I) (Wuttke et al. 1971) and pituitary DA receptor sites (Meites 1977; MacLeod & Login 1977) Preliminary results in animals (Cocchi et al.
1979
) and humans (Müller et al. 1978) suggested that nomifensine (Nom), a new antidepressant drug which activates DA neurotransmission mainly by inhibiting DA re-uptake (Hunt et al. 1974) The criterion adopted to define 'responsiveness' to Nom was that of basal Prl level suppression of 30% or more in at least three consecutive samples collected within the 120-240 min post-treatment interval. This criterion was adopted on the basis of results gathered in puerperal hyperprolactinaemia where the minimum plasma Prl fall after Nom had this figure and timing (see Table 2 ). In addition, 7 puerperal women and 7 Nomresponder patients ( corresponding to 1 ng NIH F-l. The sensitivity of the assay is 1.0 ng/ml and the intra-assay variation 4.3 ± 1.2% (sd). The upper limit of normal in our laboratories is 20 ng/ml (Genazzani et al. 1977 Nomifensine-responders Of the 11 patients of this group 10 were charac¬ terized by the presence of a radiologically normal sella turcica and basal Prl levels lower than 50 ng/ml. Only 1 subject (Case 37) presented with Prl levels between 52-92 ng/ml and a double profile of the sella turcica (Tables 1 and 4 ). In 7 of the same subjects 44 , 45) administration of placebo was followed by some decrease in basal Prl levels (less than 20% inhibition from 90 to 240 min), which was however, significantly lower than that induced by Nom (P<0.01 at all time intervals). Fig. 2 (Table 1) .
Discussion
The results of the present study indicate that Nom is capable of lowering plasma Prl levels in both normo-and hyperprolactinaemic subjects. In nor¬ mal subjects the effect was directly related to the resting Prl levels, the more marked and prompt fall after drug treatment occurring in the individuals with higher basal Prl. As Nom facilitates dopamin- ergic neurotransmission at post-synaptic sites (Hunt et al. 1974 ), the pattern found may indicate the existence of an inherent greater post-synaptic dopaminergic sensitivity in the normal subjects with higher Prl levels because of a diminished pre-synaptic function (Gianutsos et al. 1974 (Mashiter et al. 1977) and the finding that in 3 subjects (Cases 10, 32 and 35,  (Fig. 3) . Recent reports of the literature (Fine & Frohman 1978; Van Loon 1978) (Frantz 1978 
